Artiva Biotherapeutics awarded Chief Medical Officer Banerjee Subhashis 30,000 shares at $0 per share on September 9, 2026, along with 85,000 derivative securities. The transactions raised his resulting holdings to 170,947 shares and 85,000 derivative securities, giving investors a clear view of the reported insider award and ownership position.
Key Highlights
- Banerjee Subhashis held 170,947 Artiva Biotherapeutics shares after the award.
- The Chief Medical Officer received 85,000 derivative securities in a separate award.
- The 30,000-share transaction represented about 17.5% of his resulting shareholding.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded Chief Medical Officer Banerjee Subhashis 30,000 shares at $0 per share on September 9, 2026. The same date also brought an award of 85,000 derivative securities.
September 9 Awards Add Shares and Derivative Securities
Banerjee’s resulting Artiva Biotherapeutics shareholding stood at 170,947 shares after the transaction. The share award represented about 17.5% of that resulting holding. Banerjee held 85,000 derivative securities following that transaction, representing about 100.0% of his resulting derivative-securities holding.
Resulting Insider Ownership Position
His post-transaction share total was 170,947, while his derivative-securities holding was 85,000. The filing classifies both transactions as awards made on September 9, 2026.
FAQs
Q: How many Artiva Biotherapeutics shares did Banerjee Subhashis receive?
A: Banerjee Subhashis received 30,000 Artiva Biotherapeutics shares at $0 per share. The award occurred on September 9, 2026, under transaction code A.
Q: What was Banerjee Subhashis’s resulting ARTV shareholding?
A: Banerjee Subhashis held 170,947 Artiva Biotherapeutics shares after the award. The 30,000-share transaction represented about 17.5% of that resulting shareholding.
Q: How many derivative securities did the Artiva executive receive?
A: Banerjee Subhashis received 85,000 derivative securities from Artiva Biotherapeutics. His resulting derivative-securities holding was 85,000, representing about 100.0% of that holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.